Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects; 18 - 40 years of age~* Body mass index between 18 and 27 kg/m2~* Written informed consent~* Normal findings in medical \& bleeding history~* Non-smoking~Exclusion Criteria:~* Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration~* Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease)~* Known disorders with increased bleeding risk (e.g. peridontosis, haemorrhoids, acute gastritis, peptic ulcer, intestinal ulcer)~* Known sensitivity to common causes of bleeding (e.g. nasal)~* History of thromboembolism~* History of occlusive vascular diseases~* History of vascular anomalies~* History of hypercholesterolemia~* History of myopathy~* Impaired liver function (AST, ALT, gGT, bilirubin \> 3 x ULN)~* Impaired renal function (serum creatinine \> 1.3 mg/dl)~* Elevated creatinine-kinase or serum-myoglobin (\> 3 x ULN)~* Any other relevant deviation from the normal range in clinical chemistry, haematology or urine analysis~* HIV-1/2-Ab, HbsAg or HCV-Ab positive serology~* Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg~* Known allergy against any test agent under study~* Regular daily consumption of more than on litre of xanthine-containing beverages or more than 40g alcohol~* Participation in another clinical trial during the preceding 3 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): 80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15

Based on this trial design, predict the completion outcome and termination type (if applicable).